Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2/3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Sarcoma 1Dermatologic 1Breast 1

Conditions

Glioma 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 147Radiotherapy 91Cyclophosphamide 53Magnetic Resonance Spectroscopy 43Radiation 42Bevacizumab 38Irinotecan 34Filgrastim 29Radiosurgery 27Specimen Handling 25Nivolumab 25Carboplatin 24Topotecan 23Etoposide 22fludarabine 20Surgical Procedures, Operative 20pembrolizumab 19Vorinostat 18Vincristine 18Melphalan 17Granulocyte Colony-Stimulating Factor 17sargramostim 15Peripheral Blood Stem Cell Transplantation 14Ipilimumab 14Drug Therapy 13temsirolimus 12Sirolimus 12Radiotherapy, Intensity-Modulated 12O(6)-benzylguanine 12Everolimus 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × tozuleristide × CNS × Clear all
NCT02462629 2023-02-21

Study of BLZ-100 in Pediatric Subjects With CNS Tumors

Blaze Bioscience Inc.

Phase 1 Completed
29 enrolled
CNS

Brain Neoplasms, Central Nervous System Neoplasms

NCT02234297 2016-04-06

Safety Study of BLZ-100 in Adult Subjects With Glioma Undergoing Surgery

Blaze Bioscience Inc.

Phase 1 Completed
17 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡